New Technology– category –
-
USC Viterbi Engineers Develop Ultrasound-Guided SHIFTERS Technology to Reprogram Solid Tumors for CAR-T Efficacy
USC Viterbi School of Engineering USA Overview Researchers at the USC Viterbi School of Engineering have developed a novel technology called SHIFTERS to enable CAR-T cells to effectively target solid tumors. This method uses focused ultr... -
Novartis’ CAR-T Cell Therapy Tisagenlecleucel Shows Durable Efficacy in Pediatric and Young Adult ALL
CancerNetwork USA Overview Novartis' CAR-T cell therapy, tisagenlecleucel (Kymriah), continues to demonstrate durable efficacy and safety in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia ... -
Groundbreaking CAR-T Cell Therapy Achievement: Multiple Myeloma Patient Attains Decade-Long Remission After Exhausting Chemotherapy Options
Stanford Medicine Facebook USA Overview A patient with advanced multiple myeloma achieved a remarkable 10-year remission after participating in a CAR-T cell therapy trial at the Fred and Pamela Buffett Cancer Center. Despite exhausting c... -
Clinical Progress of Engineered Cellular Immunotherapies for Autoimmunity: Diverse Modalities Pioneer New Treatment Avenues
PMC - NIH USA Overview Clinical development of engineered cellular immunotherapies for autoimmune diseases is rapidly advancing, poised to offer novel therapeutic options. Diverse modalities, including CAR-T cells, CAR-NK cells, and TCR-... -
Epigenome Editing of Human Hematopoietic Stem Cells Achieves Sustained and Reversible Thrombosis Prevention
preLights (The Company of Biologists) Unknown Overview A groundbreaking study demonstrated that epigenome editing of human hematopoietic stem cells (HSCs) enables sustained and reversible thrombosis prevention. This innovative technology... -
IPS HEART Secures FDA Rare Pediatric Disease Designation for Muscular Dystrophy-Associated Cardiomyopathies, Accelerating Cardiac Regenerative Medicine Development
BioSpace USA Overview IPS HEART has received Rare Pediatric Disease Designation (RPDD) from the U.S. FDA for its iPSC-derived therapeutic candidate for muscular dystrophy-associated cardiomyopathies. This marks the company's 8th FDA regu... -
In Vivo CAR-T Cell Therapy Achieves Clinical Proof of Concept; AI Integration Poised to Revolutionize Cancer Treatment
OncoDaily Unknown Overview In vivo CAR-T cell therapy has achieved initial clinical proof of concept, demonstrating its potential to transform cancer treatment. This novel approach directly delivers and expresses CAR genes in T-cells wit... -
CEA-Targeted CAR-NK Cells Derived from iPSCs Demonstrate Potent Anti-Tumor Activity Against Colorectal Cancer
Frontiers in Immunology Unknown Overview A new study reports that chimeric antigen receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) exhibit potent anti-tumor activity against colorectal cancer. These CEA-target... -
Texas Children’s Hospital Establishes Cell and Gene Therapy Innovation Hub to Accelerate Development and Expand Access
Texas Children's Hospital USA Overview Texas Children's Hospital has established a new innovation hub to accelerate breakthroughs in cell and gene therapy (CGT). This comprehensive facility centralizes all necessary resources and experti... -
RiboX Therapeutics Receives FDA IND Clearance for RXIM002, the First Circular RNA-Based In Vivo CAR Therapy for Autoimmune Cytopenias
BioSpace USA Overview RiboX Therapeutics has received FDA Investigational New Drug (IND) clearance for RXIM002, a circular RNA (circRNA)-based in vivo CAR therapy targeting autoimmune cytopenias. RXIM002 is the first in vivo CAR therapy ...
